Watch Damian Wild discuss the role of nuclear medicine physicians in multidisciplinary oncology tumor boards, strategies for engaging oncologists in the theranostics-related management of their patients, and the future of dosimetry in clinical practice. He also shares valuable insights for young professionals exploring opportunities in theranostics.

Heloisa Soares examined the unmet need in managing neuroendocrine tumors (NETs), the impact of current phase 3 trials on the management of well-differentiated NETs, the role of molecular profiling in neuroendocrine neoplasm management, and how future guidelines for gastroenteropancreatic NETs may change with the recent theranostics developments.

This webcast is from the satellite symposium titled “HOW TO SPEAK ‘THERANOSTICS’ IN NET: Translating Key Principles into Clinical Practice” that took place at the European Neuroendocrine Tumor Society (ENETS) Annual Congress on 6^th March 2025 in Krakow, Poland.